.

Pharmaceutical Business Intelligence

  • Find generic sources and suppliers
  • Uncover prior art in abandoned patent applications and expired patents
  • Drug patents and clinical trials in dozens of countries

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

UPTRAVI Drug Profile

« Back to Dashboard

Which patents cover Uptravi, and what substitute generic drugs are available?

Uptravi is a drug marketed by Actelion Pharms Ltd and is included in one NDA. There are four patents protecting this drug.

This drug has sixty-four patent family members in twenty-five countries.

The generic ingredient in UPTRAVI is selexipag. One supplier is listed for this compound. Additional details are available on the selexipag profile page.

Summary for Tradename: UPTRAVI

Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list26
Patent Applications: see list24
Drug Prices:see details
DailyMed Link:UPTRAVI at DailyMed

Pharmacology for Tradename: UPTRAVI

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actelion Pharms Ltd
UPTRAVI
selexipag
TABLET;ORAL207947-007Dec 21, 2015RXYesNo► Subscribe► Subscribe
Actelion Pharms Ltd
UPTRAVI
selexipag
TABLET;ORAL207947-006Dec 21, 2015RXYesNo7,205,302► SubscribeYY ► Subscribe
Actelion Pharms Ltd
UPTRAVI
selexipag
TABLET;ORAL207947-008Dec 21, 2015RXYesYes9,284,280► Subscribe ► Subscribe
Actelion Pharms Ltd
UPTRAVI
selexipag
TABLET;ORAL207947-005Dec 21, 2015RXYesNo8,791,122► SubscribeYY ► Subscribe
Actelion Pharms Ltd
UPTRAVI
selexipag
TABLET;ORAL207947-006Dec 21, 2015RXYesNo9,284,280► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: UPTRAVI

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,340,516Form-II crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl) acetamide, method for producing the same, and use thereof► Subscribe
9,440,931Form-III crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide and use thereof► Subscribe
8,809,334Therapeutic compositions containing macitentan► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: UPTRAVI

Country Document Number Estimated Expiration
Japan4479152► Subscribe
Colombia6430432► Subscribe
Netherlands300836► Subscribe
South Africa201109099► Subscribe
Mexico2011013471► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: UPTRAVI

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0836Netherlands► SubscribePRODUCT NAME: SELEXIPAG OF EEN ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/15/1083 20160519
266Luxembourg► SubscribePRODUCT NAME: SELEXIPAG OU UN SEL DE CELUI-CI; FIRST REGISTRATION DATE: 20160519
2016 00048Denmark► SubscribePRODUCT NAME: SELEXIPAG ELLER ET SALT DERAF; REG. NO/DATE: EU/1/15/1083 20160519
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc